Evidence map›Paper›PMID 27275207›Full record

ArticleOpen access Macedonian journal of medical sciences2015

Significance of Serum Cytokeratin-18 in Prediction of Hepatocellular Carcinoma in Chronic Hepatitis C Infected Egyptian Patients.

Wafaa El-Zefzafy, Hanan Eltokhy, Nagwa Abd El-Ghaffar Mohamed, Zakia Abu-Zahab

Open access · diamondAbstract read
In one paragraph

Article in Open access Macedonian journal of medical sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Cytokeratin-18 in Diagnosis of HCC in Patients with Liver CirrhosisAsian Pacific journal of cancer prevention : APJCP · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Wafaa El-ZefzafyFaculty of Medicine for Girls Al-Azhar University, Tropical Medicine, Cairo, Egypt.
Hanan EltokhyFaculty of Medicine for Girls Al-Azhar University, Internal Medicine, Cairo, Egypt.
Nagwa Abd El-Ghaffar MohamedDepartment of Clinical and Chemical Pathology, National Research Center, AL-Tahreer Street, AL-Dokki, Giza, Cairo 12622, Egypt.
Zakia Abu-ZahabFaculty of Medicine for Girls Al-Azhar University, Clinical Pathology, Cairo, Egypt.
Al Azhar University · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis C virus is one of the most common etiologic agents of chronic liver diseases, including liver cirrhosis and hepatocellular carcinoma in which there is continuous inflammation and regeneration of hepatocytes. Cytokeratin-18 (CK18) has been suggested to play an important role in tumorigenesis of epithelial cancers.

aimEstimation of CK18 serum levels in patients with chronic viral hepatitis C (CHCV) and hepatocellular carcinoma (HCC) and find the relationship between their levels, the severity of the disease and the development of HCC.

methodsWe measured serum levels of CK18 in 60 Egyptian patients (30 with CHCV & 30 with HCC) and 30 healthy controls.

resultsPatients with HCC had highly significant increased CK18 levels compared with CHCV patients, healthy controls. Cytokeratin-18 among the three classes of Child-Pugh classification show highly significant gradual increase from child A to C. Furthermore, In HCC there were positive correlations between CK18 and with RBCs, ESR, and AFP.

conclusionCK18 is a sensitive indicator of the severity of liver disease. Patients with CHCV infection can be followed up by measurement of its serum level which can predict the development of HCC. The combination of AFP and CK18 increased the sensitivity of detection for HCC.

Indexed as

Cytokeratin-18HCCtumor markerviral hepatitisα-fetoprotein

Identifiers

PMID27275207
PMCPMC4877768
OpenAlexW1967858214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.